MPL mutations in myeloproliferative disorders: analysis of the PT1 cohort
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders: Inhibition of Jak2-dependent Systems by AT9283
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
